90
Participants
Start Date
October 15, 2019
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2025
Zanubrutinib
Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily or 320mg once daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
Tennessee Oncology, Pllc Nashville, Nashville
Texas Oncology McAllen South Second Street, McAllen
Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
Rocky Mountain Cancer Centers (Williams) Usor, Aurora
Christiana Care, Newark
Scri Florida Cancer Specialists South, Fort Myers
St Century Oncology, Jacksonville
Scri Florida Cancer Specialists North, St. Petersburg
Healthcare Research Network Iii, Llc, Flossmoor
Minnesota Oncology Burnsville Clinic, Burnsville
Comprehensive Cancer Centers of Nevada, Las Vegas
Summit Medical Group, Florham Park
Morristown Medical Center, Morristown
Clinical Research Alliance, Inc, Westbury
St Lukes University Health Network, Fountain Hill
Abington Hematology Oncology Associates, Horsham
Texas Oncology Amarillo, Amarillo
Texas Oncology Tyler Longview, Austin
Baylor Research Institute, Dallas
Us Oncology Virginia Cancer Specialists, Pc, Fairfax
Virginia Oncology Associates, Norfolk
Fred Hutchinson Cancer Research Center, Seattle
Medical Oncology Associates, Spokane
Ssm Health Cancer Care Dean Medical Center, Madison
Lead Sponsor
BeiGene
INDUSTRY